Dark

Check out our Level2View

BCTXL
BriaCell Therapeutics Corp. Warrant expiring 2031
stock NASDAQ Warrant

At Close

Jul 30, 2026 3:59:30 PM EDT

0.9100USD0.000%(+0.9100)1,601

0.00Bid 0.00Ask 0.0000Spread

Pre-market

0.00USD0.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsTrends

BCTXL Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

BCTXL Specific Mentions

As of Aug 1, 2026 7:47:10 AM EDT (1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

130 days ago • u/kevinb15 • r/pennystocks • briacell_phase_3_cancer_vaccine_results_expected • :DDNerd: 🄳🄳 :DDNerd: • B

BriaCell (BCTX) is working on a cancer vaccine for late-stage breast cancer patients
who have already tried multiple treatments and run out of options.
In their Phase 2 study, patients who received the vaccine alongside a standard
immunotherapy drug lived a median of 20 months. Patients in this situation typically
live 13-16 months on current treatments. The disease was controlled in over 90% of
the matched patients.
They're now in a Phase 3 trial (the final stage before FDA approval) and results
are expected within months. No cancer vaccine like this has ever made it through
Phase 3 before, so this is high risk. But the Phase 2 numbers were
unusually strong for this patient population.
One thing worth knowing: there's a warrant (BCTXL) that trades around $1 alongside
the common stock (~$5). The company has done two reverse stock splits in the past
year, which has complicated the older warrants. BCTXL is the cleaner one to
understand if you're looking at the warrant side.

130 days ago • u/kevinb15 • r/pennystocks • briacell_phase_3_cancer_vaccine_results_expected • :DDNerd: 🄳🄳 :DDNerd: • B

BriaCell (BCTX) is working on a cancer vaccine for late-stage breast cancer patients
who have already tried multiple treatments and run out of options.
In their Phase 2 study, patients who received the vaccine alongside a standard
immunotherapy drug lived a median of 20 months. Patients in this situation typically
live 13-16 months on current treatments. The disease was controlled in over 90% of
the matched patients.
They're now in a Phase 3 trial (the final stage before FDA approval) and results
are expected within months. No cancer vaccine like this has ever made it through
Phase 3 before, so this is high risk. But the Phase 2 numbers were
unusually strong for this patient population.
One thing worth knowing: there's a warrant (BCTXL) that trades around $1 alongside
the common stock (~$5). The company has done two reverse stock splits in the past
year, which has complicated the older warrants. BCTXL is the cleaner one to
understand if you're looking at the warrant side.

Share